Compugen ((CGEN)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Compugen Ltd is currently recruiting participants for a clinical trial titled An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC). The study aims to assess whether COM701, an experimental antibody, can delay the progression of ovarian cancer and its safety profile.
The trial is testing COM701, administered intravenously every three weeks, as both a standalone treatment and in combination with other anti-cancer drugs. The primary goal is to determine if COM701 can slow or stop cancer progression and delay the need for new treatments.
This interventional study uses a randomized, parallel, triple-masked design. Participants are randomly assigned to receive either COM701 or a placebo, with a 67% chance of receiving the experimental drug. The primary purpose is treatment, and the study includes regular safety and efficacy reviews by a data monitoring committee.
The study began on July 22, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on the same start date, indicating active recruitment and ongoing study activities.
The successful development of COM701 could positively impact Compugen’s stock performance by enhancing investor confidence in its pipeline. This trial’s progress is crucial in the competitive oncology market, where innovative treatments are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.